Key result
Mesenchymal stem cells possess immunomodulatory features and demonstrate potential in experimental models to reduce cardiac injury and improve cardiac function in inflammatory cardiomyopathy.
Mesenchymal stem cells offer a promising therapeutic strategy for inflammatory cardiomyopathy due to their immunomodulatory features and ability to home to the heart and improve myocardial function.
No takes yet. Share an insight, caveat, or question.
Caution against routine MSC use in inflammatory cardiomyopathy; leaves open efficacy pending randomized trials.
Linthout et al. (2011) conducted a review in Inflammatory cardiomyopathy. Mesenchymal stem cells (MSCs) was evaluated. Mesenchymal stem cells possess immunomodulatory features and demonstrate potential in experimental models to reduce cardiac injury and improve cardiac function in inflammatory cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: